Jennifer A Limond1, Kim S Bull2, Gabriele Calaminus3, Colin R Kennedy4, Helen A Spoudeas5, Mathilde P Chevignard6. 1. Mental Health and Wellbeing, University of Glasgow, Glasgow, UK. Electronic address: Jennifer.Limond@glasgow.ac.uk. 2. Faculty of Medicine, University of Southampton, Southampton, UK. 3. Pediatric Hematology and Oncology, University Hospital Münster, Münster, Germany. 4. Faculty of Medicine, University of Southampton, Southampton, UK; University Hospital Southampton NHS Foundation Trust, Southampton, UK. 5. Paediatric Endocrinology, University College London Hospital and Great Ormond Street Hospital, London, UK. 6. Rehabilitation Department for children with acquired neurological injury, Saint Maurice Hospitals, Saint Maurice, France; Sorbonne Universités, UPMC Univ Paris 06, UMR 7371, UMR_S 1146, LIB, F-75005, Paris, France.
Abstract
INTRODUCTION: There is increasing recognition of the long-term sequelae of brain tumours treated in childhood. Five year survival rates now exceed 75% and assessing the quality of survival (QoS) in multiple domains is essential to any comparison of the benefits and harms of treatment regimens. AIM: The aim of this position statement is to rationalise assessments and facilitate collection of a common data set across Europe. Sufficient numbers of observations can then be made to enable reliable comparisons between outcomes following different tumour types and treatments. METHODS: This paper represents the consensus view of the QoS working group of the Brain Tumour group of the European Society of Paediatric Oncology regarding domains of QoS to prioritise for assessment in clinical trials. This consensus between clinicians and researchers across Europe has been arrived at by discussion and collaboration over the last eight years. RESULTS: Areas of assessment discussed include core medical domains (e.g. vision, hearing, mobility, endocrine), emotion, behaviour, adaptive behaviour and cognitive functioning. CONCLUSIONS: A 'core plus' approach is suggested in which core assessments (both direct and indirect tests) are recommended for all clinical trials. The core component is a relatively brief screening assessment that, in most countries, is a sub-component of routine clinical provision. The 'plus' components enable the addition of assessments which can be selected by individual countries and/or tumour-, age-, and location-specific groups. The implementation of a QoS protocol common to all European clinical studies of childhood brain tumours is also discussed.
INTRODUCTION: There is increasing recognition of the long-term sequelae of brain tumours treated in childhood. Five year survival rates now exceed 75% and assessing the quality of survival (QoS) in multiple domains is essential to any comparison of the benefits and harms of treatment regimens. AIM: The aim of this position statement is to rationalise assessments and facilitate collection of a common data set across Europe. Sufficient numbers of observations can then be made to enable reliable comparisons between outcomes following different tumour types and treatments. METHODS: This paper represents the consensus view of the QoS working group of the Brain Tumour group of the European Society of Paediatric Oncology regarding domains of QoS to prioritise for assessment in clinical trials. This consensus between clinicians and researchers across Europe has been arrived at by discussion and collaboration over the last eight years. RESULTS: Areas of assessment discussed include core medical domains (e.g. vision, hearing, mobility, endocrine), emotion, behaviour, adaptive behaviour and cognitive functioning. CONCLUSIONS: A 'core plus' approach is suggested in which core assessments (both direct and indirect tests) are recommended for all clinical trials. The core component is a relatively brief screening assessment that, in most countries, is a sub-component of routine clinical provision. The 'plus' components enable the addition of assessments which can be selected by individual countries and/or tumour-, age-, and location-specific groups. The implementation of a QoS protocol common to all European clinical studies of childhood brain tumours is also discussed.
Authors: L Veneroni; L Boschetti; F Barretta; C A Clerici; F Simonetti; E Schiavello; V Biassoni; F Spreafico; L Gandola; E Pecori; B Diletto; G Poggi; F Gariboldi; R Sensi; M Massimino Journal: Childs Nerv Syst Date: 2017-08-02 Impact factor: 1.475
Authors: Matthew C H J Morrall; Rosa Reed-Berendt; Kate Moss; Helen Stocks; Alexandra L Houston; Poppy Siddell; Susan Picton; Richard Grundy Journal: Childs Nerv Syst Date: 2018-12-15 Impact factor: 1.475
Authors: David T W Jones; Mark W Kieran; Eric Bouffet; Sanda Alexandrescu; Pratiti Bandopadhayay; Miriam Bornhorst; David Ellison; Jason Fangusaro; Michael J Fisher; Nicholas Foreman; Maryam Fouladi; Darren Hargrave; Cynthia Hawkins; Nada Jabado; Maura Massimino; Sabine Mueller; Giorgio Perilongo; Antoinette Y N Schouten van Meeteren; Uri Tabori; Katherine Warren; Angela J Waanders; David Walker; William Weiss; Olaf Witt; Karen Wright; Yuan Zhu; Daniel C Bowers; Stefan M Pfister; Roger J Packer Journal: Neuro Oncol Date: 2018-01-22 Impact factor: 12.300
Authors: Elizabeth M Wells; Nicole J Ullrich; Kristy Seidel; Wendy Leisenring; Charles A Sklar; Gregory T Armstrong; Lisa Diller; Allison King; Kevin R Krull; Joseph P Neglia; Marilyn Stovall; Kimberly Whelan; Kevin C Oeffinger; Leslie L Robison; Roger J Packer Journal: Neuro Oncol Date: 2018-01-10 Impact factor: 12.300
Authors: Hugo Câmara-Costa; Kim S Bull; Colin Kennedy; Andreas Wiener; Gabriele Calaminus; Anika Resch; Virginie Kieffer; Clémence Lalande; Geraldina Poggi; Katja von Hoff; Jacques Grill; François Doz; Stefan Rutkowski; Maura Massimino; Rolf-Dieter Kortmann; Birgitta Lannering; Georges Dellatolas; Mathilde Chevignard Journal: Neurooncol Pract Date: 2017-02-10
Authors: Sharon H O'Neil; Ashley M Whitaker; Kimberly Kayser; Mary Baron Nelson; Jonathan L Finlay; Girish Dhall; Stephen Sands Journal: Neurooncol Pract Date: 2020-02-03